Porton Pharma Solutions saw the highest growth of 2.99% in patent filings in April and 0.99% in grants in June in Q2 2024. Compared to Q1 2024, Q2 2024 saw an increase in patent filings by 2.99% and no change in grants. GlobalData’s DataBook provides a comprehensive analysis of Porton Pharma Solutions‘s patent filings and grants. Buy the databook here.
Porton Pharma Solutions has been focused on protecting inventions in United States(US) with five publications in Q2 2024
The United States(US) Patent Office dominates the patent filings and grants with nearly 67% filings and 25% grants. The United States(US), European Patent Office(EPO), and China(CN) patent Office are among the top ten patent offices where Porton Pharma Solutions is filings its patents. Among the top granted patent authorities, Porton Pharma Solutions has 75% of its grants in China(CN) and 25% in United States(US).
Bayer and Roche could be the strongest competitors for Porton Pharma Solutions
Patents related to rare diseases lead Porton Pharma Solutions's portfolio
Porton Pharma Solutions has the highest number of patents in rare diseases. For rare diseases no patents were filed and 100% of patents were granted in Q2 2024.
Petrochemicals related patents lead Porton Pharma Solutions portfolio followed by biliary atresia, and pulmonary fibrosis
Porton Pharma Solutions has highest number of patents in petrochemicals followed by biliary atresia, pulmonary fibrosis, lung disease, and fibrosis.
For comprehensive analysis of Porton Pharma Solutions's filings and grants, buy the databook here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.